Latest Mitral regurgitation Stories
--Proceeds Will be Used To Fund New Initiative to Treat Mitral Valve Disease and to Complete Neovasc Reducer(TM) COSIRA Trial for Treating Refractory Angina-- TSX Venture Exchange: NVC VANCOUVER, July 21, 2011 /PRNewswire/ - Neovasc Inc.
STOUGHTON, Mass., July 20, 2011 /PRNewswire/ -- STD Med, Inc., a worldwide manufacturer and innovator of medical devices located in Stoughton, Massachusetts, is pleased to announce that one of its internally incubated medical device technologies, Spirus Medical, Inc., has been successfully acquired by Olympus Corporation.
Individuals with diastolic dysfunction (impaired relaxation of the heartâ€™s ventricle after contraction) appear to have increased risk of death, regardless of whether their systolic function (contraction of the ventricle) is normal or they have other cardiovascular impairments, according to this study.
An innovative approach for implanting a new aortic heart valve without open-heart surgery is being offered at Rush University Medical Center to patients with severe aortic stenosis who are at high-risk or not suitable candidates for open heart valve replacement surgery.
KIRKLAND, Wash., May 4, 2011 /PRNewswire/ -- Cardiac DimensionsÂ®, Inc. announced today the initiation of two new clinical studies using the CARILLONÂ® Mitral Contour System(TM), an investigational device for percutaneous treatment of Functional Mitral Regurgitation (FMR).
Measuring oxidative stress may help doctors predict the risk of developing atrial fibrillation, the most common heart beat irregularity.
NorthShore University HealthSystem's Ted Feldman, MD, Presents Late Breaking Data at American College of Cardiology Conference EMBARGOED FOR RELEASE UNTIL 8 AM, CDT, APRIL 4, 2011 EVANSTON, Ill., April 4, 2011 /PRNewswire-USNewswire/ -- NorthShore University HealthSystem (NorthShore) interventional cardiologist, Ted Feldman, MD, presented positive results from the EVEREST II trial (Endovascular Valve Edge-to-Edge REpair STudy), that were concurrently published in The New England Journal of...
NEW ORLEANS, April 4, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from its EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study showing that patients with significant mitral regurgitation (MR) treated with the company's investigational percutaneous catheter-based MitraClipÂ® system continue to demonstrate the clinical benefits of initial treatment shown at one year out to two years, including improvements in heart function and reductions in symptoms.
NYU Langone Medical Center surgeons are performing minimally invasive heart surgery techniques on patients in their 80s and 90s.
ABBOTT PARK, Ill., March 30, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the launch of the company's catheter-based MitraClipÂ® system for the treatment of mitral regurgitation (MR) in Australia.